According to Insulet's latest financial reports the company has a price-to-book ratio of 16.6.
The price-to-book ratio is a way to measure how much the stock market thinks a company is worth compared to how much the company says its assets are worth on paper.
Year | P/B ratio | Change |
---|---|---|
2023-12-31 | 20.7 | -51.82% |
2022-12-31 | 42.9 | 30.1% |
2021-12-31 | 33.0 | 18.14% |
2020-12-31 | 27.9 | -80.25% |
2019-12-31 | 141 | 538.77% |
2018-12-31 | 22.1 | -12.61% |
2017-12-31 | 25.3 | -26.08% |
2016-12-31 | 34.3 | -45.82% |
2015-12-31 | 63.2 | 104.45% |
2014-12-31 | 30.9 | 89.33% |
2013-12-31 | 16.3 | -29.67% |
2012-12-31 | 23.2 | 115.35% |
2011-12-31 | 10.8 | 1.43% |
2010-12-31 | 10.6 | 4.26% |
2009-12-31 | 10.2 | 44.87% |
2008-12-31 | 7.04 | 7.95% |
2007-12-31 | 6.52 | |
2006-12-31 | N/A | |
2005-12-31 | N/A |
Company | P/B ratio | differencediff. | Country |
---|---|---|---|
Johnson & Johnson JNJ | 5.25 | -68.34% | ๐บ๐ธ USA |
Abbott Laboratories ABT | 4.73 | -71.44% | ๐บ๐ธ USA |
Medtronic MDT | 2.07 | -87.53% | ๐ฎ๐ช Ireland |
Eli Lilly LLY | 66.1 | 299.02% | ๐บ๐ธ USA |
Tandem Diabetes Care
TNDM | 7.53 | -54.59% | ๐บ๐ธ USA |
ICU Medical
ICUI | 1.14 | -93.14% | ๐บ๐ธ USA |
DexCom DXCM | 22.4 | 35.26% | ๐บ๐ธ USA |